Key success factors for a life sciences cluster The case of Flanders LIFE SCIENCES AT THE HEART OF EUROPE

Size: px

Start display at page:

Download "Key success factors for a life sciences cluster The case of Flanders LIFE SCIENCES AT THE HEART OF EUROPE"

Douglas Hines
7 years ago
Views:

1 Key success factors for a life sciences cluster The case of Flanders LIFE SCIENCES AT THE HEART OF EUROPE Flanders Investment and Trade, Government of Flanders Belgium, 2015

2 The innovation system Community builders Excellent R&D infrastructure Supportive Government Human capital Serial entrepreneurs Life sciences cluster Seed funding, Private equity and Venture Capital Industry leaders Incubators and accelerators

A clear strategy Aging population: rise of chronic diseases, cancer, neurodegenerative diseases Increasing complexity of biomedical devices and targeting disease mechanisms Economics: - Cost of

3 A clear strategy Aging population: rise of chronic diseases, cancer, neurodegenerative diseases Increasing complexity of biomedical devices and targeting disease mechanisms Economics: - Cost of drug development - Limited resources Long-term strategic policy on research and development to maximize our knowledge economy Disruptive technologies: - Nanobiotechnologies - IT-health (incl. big data)

4 Cover the range of innovation R&D infrastructure 5 Universities 20+ university colleges 5 strategic R&D centers Global Clinical Center University Hospitals Int l accredited Private Hospitals CRO Hub at the heart of Europe Pioneer in Electronic Patient Records Venture-friendly 15 Life sciences incubators & Business parks VC community Serial entrepreneurs Attractive benefits Extensive Tech transfer offices Proven industry 150 biotech companies 380 life sciences companies +20,000 jobs directly Home to all big pharma Nr. 1 on the stock market

5 Institute for Biotechnology - VIB Interuniversity Institute to conduct frontline biomolecular research in life sciences for the benefit of scientific progress and the benefit of society. Research at 8 departments at 4 universities [72 R&D groups] Department for Molecular Biomedical Research (Ghent) Department of Plant Systems Biology (Ghent) Department of Transgene Technology and Gene Therapy (Leuven) Department of Molecular and Developmental Genetics (Leuven) Department of Molecular and Cellular Interactions (Brussels) Department of Molecular Genetics (Antwerp) Department of Medical Protein Research (Ghent) Department of Molecular Microbiology (Leuven) Industry collaborations Facts & figures: Jo Bury, Johan Cardoen Staff: 1,300 Startups: 12 Ablynx, Actogenix, CropDesign, Devgen, Pronota, Multiplicom, Q-Biologicals, Bio- Incubator Leuven, Biolign, FlandersBio, Solucel Budget : 84 million EUR Government grant : 45 million EUR Founding partner of NERF Successful spinoffs

52,000 students - 24,000 in sciences, applied sciences and (Bio)medical.

6 Innovation example: Leuven IMEC K.U.Leuven Largest nanotech R&D center in EU NeuroElectronics Research Facility World s largest industry consortium with Intel, Samsung, TI, Gasthuisberg Established in ,000 students - 24,000 in sciences, applied sciences and (Bio)medical. One off Europe s oldest and most experienced Tech Transfer Offices Member of VIB Arenberg & Haasrode parks Community Bio-incubators, IT cluster, new venture facility Easy access to Univ. and IMEC Europe s largest university hospital [+2,000 beds] Campus Biomedical Sciences Integrated approach Global Clinical Center Leuven.Inc network Venture capital and business angels 130 spinoffs of Univ and IMEC

7 Health Sciences Campus Leuven UZ Leuven Research campus - Beds: 2,480 - Annual budget: 800 MEUR - Staff: 9,000 - Clinical trials: +1,100/yr, +800 commercial trials with 250 different sponsors, 100 CROs Hospital Ambulant Biomedical education Master plan expansion: - Hospital-school Child & Youth Psychiatry - Women & Child Building - Oncology Building - Operating room expansion - Critical Care Services

8 The importance of consortia: IMEC

9 Nanotech for health

10 All ingredients Highest concentration of big pharma, with extensive R&D, regulatory, manufacturing and logistics facilities Large medtech companies with EU HQ Fast-growing biotech startups Wide range of medtech companies Dynamic cluster organizations

11 Drug development

12 Big pharma Big in Belgium Ghent Antwerp Brussels Capital Region

13 Dynamic biotech scene: examples Ghent Antwerp Brussels Leuven

14 Medtech hub Ghent Antwerp Brussels Leuven Hasselt

in Flanders Life sciences industry association 270 members

15 Organized industry European cluster of excellence in Smart Electronic Systems Network of Medical Device development in Flanders Life sciences industry association 270 members

ABLYNX COMPLETES 40 MILLION (~US$50 MILLION) SERIES C FINANCING ONE OF THE TWO LARGEST PRIVATE PLACEMENTS IN EUROPEAN BIOTECH THIS YEAR

FOR IMMEDIATE RELEASE ABLYNX COMPLETES 40 MILLION (~US$50 MILLION) SERIES C FINANCING ONE OF THE TWO LARGEST PRIVATE PLACEMENTS IN EUROPEAN BIOTECH THIS YEAR GHENT, Belgium, 23 August 2006 Ablynx, the